Galactooligosaccharides (GOS)
Trans-galactooligosaccharides
A lactose-derived prebiotic fiber that is reliably bifidogenic and may aid constipation and immune/metabolic markers, but is itself a FODMAP that can trigger gas and IBS symptoms.
Evidence tier
Moderate
Research weight
Citations
12 verified / 12
Classification
Prebiotics & Fibers
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Galactooligosaccharides (GOS)?
Galactooligosaccharides (GOS) (Trans-galactooligosaccharides) is a prebiotic fiber used for reliably bifidogenic: randomized trials consistently show gos increases beneficial gut bifidobacterium (and lactose-fermenting lactobacillus/lactococcus) and boosts short-chain fatty acids such as acetate and butyrate — the best-established effect. NutriDex grades the human evidence as Moderate. Galactooligosaccharides (GOS, also called trans-galactooligosaccharides or B-GOS) are non-digestible fibers manufactured enzymatically from lactose. The single most consistent, well-replicated finding across randomized trials is a strong bifidogenic effect: GOS selectively increases gut Bifidobacterium and short-chain fatty acid (acetate, butyrate) production, even at low doses. Beyond microbiome shifts, randomized data are more modest and mixed: GOS has improved calcium absorption in adolescent girls, lowered some metabolic-syndrome and inflammatory markers (CRP, insulin, lipids) in overweight and elderly adults, modestly increased stool frequency in constipated adults, and in one small trial reduced the waking cortisol response. Importantly, GOS is itself a fermentable FODMAP, so the same fermentation that drives benefits can provoke gas, bloating, and worsened symptoms in people with IBS, making it a double-edged fiber.
Purported Benefits
✓Reliably bifidogenic: randomized trials consistently show GOS increases beneficial gut Bifidobacterium (and lactose-fermenting Lactobacillus/Lactococcus) and boosts short-chain fatty acids such as acetate and butyrate — the best-established effect
✓Increases intestinal calcium absorption: in a double-blind crossover trial, 5 g/day GOS raised fractional calcium absorption in adolescent girls, alongside higher bifidobacteria
✓Lowers markers of metabolic syndrome and inflammation: in overweight adults, B-GOS reduced plasma C-reactive protein, insulin, triglycerides, total cholesterol and the TC:HDL ratio while increasing secretory IgA and lowering fecal calprotectin
✓May improve immune parameters in older adults: B-GOS shifted the microbiota and modulated immune markers (e.g. increased NK-cell activity, anti-inflammatory cytokine balance) in healthy elderly volunteers
✓Modestly improves constipation: ~11 g/day increased stool frequency versus control in self-reported constipated adults, particularly those with low baseline frequency
✓May reduce incidence and duration of travellers' diarrhoea and, in one trial, lowered the cortisol awakening response and shifted attention away from negative emotional cues (gut-brain axis) — both preliminary
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Bifidogenic prebiotic effect (↑Bifidobacterium, ↑SCFA)Best-established effect; multiple RCTs show dose-dependent bifidogenic shift even at sub-prebiotic (1.3-2 g/day) doses. | Strong | ↑ benefit · large | 3 |
| Increased intestinal calcium absorptionDouble-blind crossover in adolescent girls raised fractional calcium absorption; limited to one population. | Moderate | ↑ benefit · moderate | 1 |
| Improved metabolic-syndrome and inflammatory markers (CRP, insulin, lipids)Single crossover RCT in overweight adults lowered CRP, insulin, lipids and calprotectin; not yet replicated. | Preliminary | ↑ benefit · small | 1 |
| Immune modulation in older adults (NK activity, cytokine balance)One crossover RCT in healthy elderly raised NK-cell activity and IL-10; single small trial. | Preliminary | ↑ benefit · moderate | 1 |
| Constipation relief / increased stool frequencyTwo RCTs at ~11 g/day modestly increase stool frequency, mainly in those with low baseline frequency. | Moderate | ↑ benefit · small | 2 |
| Reduced waking cortisol / gut-brain effectSingle small RCT lowered cortisol awakening response and shifted attentional bias; preliminary. | Preliminary | ↑ benefit | 1 |
| Reduced travellers' diarrhoea incidence/durationOne RCT in travellers reduced incidence and duration vs placebo; single trial. | Preliminary | ↑ benefit · moderate | 1 |
Dosing & Compounds
Typical Dose
Most trials use about 3.6-5.5 g/day of GOS (the standard B-GOS/Bimuno dose) for microbiome, immune and cortisol effects; calcium-absorption benefit was seen at ~5 g/day; constipation trials used up to ~11 g/day. Usually taken once daily as a powder mixed into food or drink, or as capsules/pastilles; start low (1-2 g/day) and titrate up over 1-2 weeks to limit gas.
Active Compounds
Safety & Cautions
GOS is generally well tolerated and is permitted in infant formula, but because it is a rapidly fermented FODMAP the main side effects are flatulence, bloating, abdominal cramping and looser stools, which are dose-dependent and worst when started abruptly or taken above ~10 g/day. People with irritable bowel syndrome (IBS) or known FODMAP sensitivity should be cautious: GOS can provoke or worsen IBS symptoms, and on a low-FODMAP diet it is one of the carbohydrates typically restricted (one trial mitigated GOS-induced symptoms with co-administered alpha-galactosidase enzyme). Unlike bulk-forming fibers such as psyllium or glucomannan, GOS does not form a viscous gel, so it carries no choking or esophageal-obstruction hazard and no strict fluid requirement. As a fermentable fiber it could theoretically alter the timing of co-ingested oral drugs, so separating from medications by a couple of hours is prudent, though clinically significant interactions are not well documented. People with galactosemia should avoid GOS, and those with severe GI disorders or who are immunocompromised should consult a clinician first. Educational only — always check with your doctor or pharmacist before combining Galactooligosaccharides (GOS) with any medicine.
Key Studies ★ 12 studies
RCT
Looijesteijn et al. 2024
✓ PubMed
In a double-blind RCT of 88 healthy women (42-70 y), even low GOS doses of 1.3 g/day and 2.0 g/day for 3 weeks significantly increased fecal Bifidobacterium relative abundance (to ~36.8% and ~42.3% respectively, p<0.01), confirming a bifidogenic effect at sub-prebiotic doses.
RCT
Lee et al. 2024
✓ PubMed
In a 4-week double-blind RCT of 63 adults with functional constipation, GOS significantly increased bowel-movement frequency versus placebo (+0.15 movements/day; 0.42 to 0.78/day, p=0.048) and improved Bristol Stool Scale scores (p=0.028) and PAC-QOL satisfaction (p=0.022).
Randomized clinical trial
Schaafsma et al. 2022 (RCT, n=132)
✓ Full text
In self-reported constipated adults, 11 g/day GOS for 3 weeks increased stool frequency versus control, particularly in subjects with low baseline frequency (<=3 bowel movements/week) and those aged >=35 years.
Randomized controlled trial
Wilson et al. 2020 (RCT)
✓ PubMed
Adding beta-GOS to a low-FODMAP diet improved IBS symptoms (67% adequate relief vs 30% control) but reduced fecal bifidobacteria, illustrating GOS's double-edged role in IBS.
Randomized controlled trial
Schmidt et al. 2015 (double-blind RCT)
✓ Full text
In 45 healthy volunteers, 5.5 g/day B-GOS for 3 weeks significantly lowered the salivary waking cortisol response and reduced attentional vigilance to negative information versus placebo and FOS, suggesting a gut-brain effect.
Randomized crossover trial
Davis et al. 2011 (double-blind RCT)
✓ PubMed
In 18 healthy adults, GOS dose-dependently increased fecal Bifidobacterium, with significant bifidogenic effect at 5 g/day and 10 g/day versus placebo, establishing GOS as a robust prebiotic.
Randomized crossover trial
Whisner et al. 2013 (double-blind crossover RCT)
✓ PubMed
In 31 adolescent girls (10-13 y), 2.5 g and 5 g/day GOS increased fractional calcium absorption (e.g. ~+10-12 percentage points at 5 g) and raised fecal bifidobacteria versus control over 3-week periods.
Randomized crossover trial
Vulevic et al. 2013 (double-blind crossover RCT)
✓ PubMed
In 45 overweight adults with metabolic-syndrome risk factors, 5.5 g/day B-GOS for 12 weeks reduced plasma CRP, insulin, triglycerides, total cholesterol and TC:HDL ratio and lowered fecal calprotectin versus maltodextrin placebo.
Randomized controlled trial
Drakoularakou et al. 2010 (double-blind RCT, n=159)
✓ PubMed
In travellers to higher-risk destinations, B-GOS supplementation significantly reduced the incidence and duration of travellers' diarrhoea and abdominal pain versus placebo.
Randomized crossover trial
Vulevic et al. 2008 (double-blind crossover RCT)
✓ PubMed
In 44 healthy elderly volunteers, 5.5 g/day B-GOS increased fecal bifidobacteria and improved immune markers (raised NK-cell activity and IL-10, lowered pro-inflammatory cytokines) versus placebo.
Review
Srisuwatchari 2026
✓ PubMed
Narrative review of hypersensitivity reactions associated with nutraceuticals and dietary supplements, GOS included.
Review
Noma 2026
✓ PubMed
Biotechnological Modulation of Legumes via Fermentation: Impacts on Nutrient Bioaccessibility, Glycemic Index, and Antinutrients-A Scoping Review